Cannell & Co. Vertex Pharmaceuticals Inc Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
A detailed history of Cannell & Co. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cannell & Co. holds 1,712 shares of VRTX stock, worth $846,772. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,712
Previous 1,712
-0.0%
Holding current value
$846,772
Previous $595,000
16.97%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding VRTX
# of Institutions
1,728Shares Held
225MCall Options Held
1.21MPut Options Held
1.44M-
Capital World Investors Los Angeles, CA26.8MShares$13.3 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$11.5 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.5 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.8 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.45 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $127B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...